Pamela Frizelle

Equilibrium Constants for (R)-[(S)-1-(4-Bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic Acid (NVP-AAM077) Acting at Recombinant NR1/NR2A and NR1/NR2B N-Methyl-d-aspartate Receptors: Implications for Studies of Synaptic Transmission

Pamela Frizelle, Philip E. Chen, David J. A. Wyllie · Molecular Pharmacology · 2006 · 129 citations

Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

Nigel Irwin, Pamela Frizelle, I. A. Montgomery et al. · Diabetologia · 2012 · 66 citations · Full text

Obesity, Metabolic Syndrome, Molecular Pharmacology +12

(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes

Nigel Irwin, Pamela Frizelle, Finbarr O’Harte et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 2013 · 23 citations

Obesity, Metabolic Syndrome, Mini-pegylated Cholecystokinin +11

Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice

Nigel Irwin, Pamela Frizelle, Finbarr O’Harte et al. · Journal of Endocrinology · 2012 · 20 citations · Full text

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

Nigel Irwin, I. A. Montgomery, Finbarr O’Harte et al. · International Journal of Obesity · 2012 · 14 citations

Obesity, Metabolic Syndrome, Subchronic Modulation +13